Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

• Mustafa Erman,
• Bivas Biswas,
• Pongwut Danchaivijitr,
• Lingwu Chen,
• Yoke Fui Wong,
• Tarek Hashem,
• Chun Sen Lim,
• Bulent Karabulut,
• Hsiao-Jen Chung,
• Chandrasekhar Chikatapu,
• Sara Ingles,
• Khemaies Slimane,
• Ravindran Kanesvaran

Affiliations

Mustafa Erman

Medical Oncology, Hacettepe University

Bivas Biswas

Medical Oncology, Tata Medical Center

Pongwut Danchaivijitr

Medical Oncology, Siriraj Hospital, Mahidol University

Lingwu Chen

Medical Oncology, The First Affiliated Hospital of Sun Yat-sen, Guangzhou

Yoke Fui Wong

Radiotherapy and Oncology, National Cancer Institute

Tarek Hashem

Medical Oncology, Dr. Tarek Hashem’s Clinic

Chun Sen Lim

Clinical Oncology, Sultan Ismail Hospital

Bulent Karabulut

Medical Oncology, Ege University

Hsiao-Jen Chung

Department of Urology, Taipei Veterans General Hospital and Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University

Chandrasekhar Chikatapu

Oncology, Novartis Healthcare Pvt. Ltd.

Sara Ingles

Oncology, Novartis Pharma AG

Khemaies Slimane

Oncology, Novartis Pharma SAS

Ravindran Kanesvaran

Division of Medical Oncology, National Cancer Centre Singapore